Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China.

Fan J, Yang GS, Fu ZR, Peng ZH, Xia Q, Peng CH, Qian JM, Zhou J, Xu Y, Qiu SJ, Zhong L, Zhou GW, Zhang JJ.

J Cancer Res Clin Oncol. 2009 Oct;135(10):1403-12. doi: 10.1007/s00432-009-0584-6. Epub 2009 Apr 21.

PMID:
19381688
2.

Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.

Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY.

Liver Transpl. 2014 Aug;20(8):945-51. doi: 10.1002/lt.23904. Epub 2014 Jul 12.

3.

[Indication of liver transplantation for hepatocellular carcinoma: Shanghai Fudan Criteria].

Fan J, Zhou J, Xu Y, Qiu SJ, Wu ZQ, Yu Y, Huang XW, Tang ZY, Wang YQ.

Zhonghua Yi Xue Za Zhi. 2006 May 16;86(18):1227-31. Chinese.

PMID:
16796876
4.

A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.

Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW.

J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.

PMID:
25690672
5.

Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.

Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK.

World J Gastroenterol. 2013 Aug 7;19(29):4737-44. doi: 10.3748/wjg.v19.i29.4737.

6.

Histological differentiation predicts post-liver transplantation survival time.

Li WX, Li Z, Gao PJ, Gao J, Zhu JY.

Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):201-8. doi: 10.1016/j.clinre.2013.11.002. Epub 2013 Dec 30.

PMID:
24388339
7.

AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.

Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, Tokat Y.

Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):256-61.

PMID:
22672818
8.

Role of surgical resection for multiple hepatocellular carcinomas.

Choi SH, Choi GH, Kim SU, Park JY, Joo DJ, Ju MK, Kim MS, Choi JS, Han KH, Kim SI.

World J Gastroenterol. 2013 Jan 21;19(3):366-74. doi: 10.3748/wjg.v19.i3.366.

9.

Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.

Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM.

Transplantation. 2008 Jun 27;85(12):1726-32. doi: 10.1097/TP.0b013e31816b67e4.

PMID:
18580463
10.

Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: a single-center experience.

Wan P, Xia Q, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, Han LZ.

J Cancer Res Clin Oncol. 2014 Feb;140(2):341-8. doi: 10.1007/s00432-013-1576-0. Epub 2013 Dec 30.

PMID:
24374832
11.

Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients.

Li J, Yan LN, Yang J, Chen ZY, Li B, Zeng Y, Wen TF, Zhao JC, Wang WT, Yang JY, Xu MQ, Ma YK.

World J Gastroenterol. 2009 Sep 7;15(33):4170-6.

12.

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Wan P, Zhang J, Long X, Li Q, Xu N, Zhang M, Chen X, Han L, Xia Q.

Eur J Gastroenterol Hepatol. 2014 May;26(5):553-61. doi: 10.1097/MEG.0000000000000070.

13.

The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis.

Zhang Q, Chen X, Zang Y, Zhang L, Chen H, Wang L, Niu Y, Ren X, Shen Z, Shang L.

PLoS One. 2012;7(12):e50919. doi: 10.1371/journal.pone.0050919. Epub 2012 Dec 7.

14.

α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.

Zhang Q, Shang L, Zang Y, Chen X, Zhang L, Wang Y, Wang L, Liu Y, Mao S, Shen Z.

Eur J Gastroenterol Hepatol. 2014 May;26(5):544-52. doi: 10.1097/MEG.0000000000000029.

PMID:
24614696
15.
16.

Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.

Varona MA, Soriano A, Aguirre-Jaime A, Garrido S, Oton E, Diaz D, Portero J, Bravo P, Barrera MA, Perera A.

Transplant Proc. 2015 Jan-Feb;47(1):84-9. doi: 10.1016/j.transproceed.2014.12.013.

PMID:
25645778
17.

Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

Lei JY, Yan LN, Wang WT.

World J Gastroenterol. 2013 Jul 21;19(27):4400-8. doi: 10.3748/wjg.v19.i27.4400.

18.

Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.

Agopian VG, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Cheng EY, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW.

JAMA Surg. 2017 Jan 1;152(1):55-64. doi: 10.1001/jamasurg.2016.3310.

19.

Living donor liver transplantation for hepatocellular carcinoma.

Isik B, Ince V, Karabulut K, Kayaalp C, Yilmaz S.

Transplant Proc. 2012 Jul-Aug;44(6):1713-6. doi: 10.1016/j.transproceed.2012.05.033.

PMID:
22841251
20.

Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma.

de Ataide EC, Garcia M, Mattosinho TJ, Almeida JR, Escanhoela CA, Boin IF.

Transplant Proc. 2012 Oct;44(8):2438-40. doi: 10.1016/j.transproceed.2012.07.006.

PMID:
23026614

Supplemental Content

Support Center